Global Information Lookup Global Information

Iniparib information


Iniparib
Clinical data
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
IUPAC name
  • 4-Iodo-3-nitrobenzamide
CAS Number
  • 160003-66-7 ☒N
PubChem CID
  • 9796068
ChemSpider
  • 7971834 checkY
UNII
  • 2ZWI7KHK8F
KEGG
  • D09913 ☒N
ChEMBL
  • ChEMBL1170047 checkY
CompTox Dashboard (EPA)
  • DTXSID30166784 Edit this at Wikidata
ECHA InfoCard100.210.980 Edit this at Wikidata
Chemical and physical data
FormulaC7H5IN2O3
Molar mass292.032 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • c1cc(c(cc1C(=O)N)[N+](=O)[O-])I
InChI
  • InChI=1S/C7H5IN2O3/c8-5-2-1-4(7(9)11)3-6(5)10(12)13/h1-3H,(H2,9,11) checkY
  • Key:MDOJTZQKHMAPBK-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Iniparib (INN,[1] previously known as BSI 201) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 (hence, a PARP inhibitor) and possibly other enzymes through covalent modification,[2][3] but its effects against PARP were later disproven.[4][5] It underwent clinical trials for treatment of some types of breast cancer,[6][7] but was discontinued after disappointing phase III clinical trials.

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. 2011. p. 68. Retrieved 20 December 2016.
  2. ^ Patel A, Kaufmann SH (January 2010). "Development of PARP inhibitors: an unfinished story". Oncology. 24 (1). Williston Park, N.Y.: 66, 68. PMID 20187324.
  3. ^ "Iniparib (BSI-201)". Our Privacy PolicyBiPar Sciences. Sanofi-Aventis. Archived from the original on 23 June 2010.
  4. ^ Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. (January 2012). "Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor". Clinical Cancer Research. 18 (2): 510–23. doi:10.1158/1078-0432.CCR-11-1973. PMID 22128301.
  5. ^ Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (March 2012). "Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro". Clinical Cancer Research. 18 (6): 1655–62. doi:10.1158/1078-0432.CCR-11-2890. PMC 3306513. PMID 22291137.
  6. ^ "BSI 201". Parp Inhibitors. Archived from the original on 9 December 2019.
  7. ^ "New breast cancer drugs block cell repair enzyme". Reuters. 2009-05-31.

and 4 Related for: Iniparib information

Request time (Page generated in 0.5349 seconds.)

Iniparib

Last Update:

Iniparib (INN, previously known as BSI 201) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of...

Word Count : 719

PARP inhibitor

Last Update:

Eisai): underwent phase II trial in melanoma. Currently Discontinued: Iniparib (BSI 201, developed by Sanofi) was determined in 2012 not to be a true...

Word Count : 2052

Otamixaban

Last Update:

anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies. "Sanofi's Investigational Iniparib, Otamixaban Fail...

Word Count : 132

Direct factor Xa inhibitors

Last Update:

Sanofi is ending development on two compounds, the anticancer compound iniparib and the anticoagulant otamixaban, both of which flunked Phase III studies...

Word Count : 1525
PDF Search Engine © AllGlobal.net